Speaker
Description
Acquired Immunodeficiency Syndrome (AIDS) is caused by Human Immunodeficiency viruses, which consist of two species of lentivirus (a subgroup of retrovirus). AIDS is a condition in humans in which progressive failure of the immune system allows life threatening opportunistic infections and cancers to thrive. Without treatment, the average survival time after infection with HIV is estimated to be 9–11 years. In India, HAART therapy includes many antiretroviral drugs (e.g., NNRTIs, protease inhibitors, infusion inhibitors, etc.), but these are becoming resistant to this highly mutative RNA virus. Scientists developed newer drugs like integrase inhibitors, ccr5 antagonists, and many more, of which ccr5 antagonists are showing promising results now, but due to blockade at the chemokine receptor, the normal functioning of CD4+ cells is getting hampered. In this crisis, PRO-140 (leronlimab) was introduced by CYTODYN INC in February 2008 and is claimed to be a humanized monoclonal antibody targeted against the ccr5 receptor. It is a candidate for a live clinical trial: a multi- A Multi-centre, two-part, single-arm, open-label, 25-week trial in treatment-experienced HIV-1 subjects. The preliminary trial is finished as of August 30, 2022, as updated at clinicaltrial.gov.in. The specifics of leronlimab (PRO-140) will be presented here, including its expected mechanism of action, clinical trial results, potential or raised adverse effects, and future prospects.